Caveolin-1 deficiency alleviates MCD-induced hepatic steatosis by coordinating ACC inhibitory phosphorylation, cholesterol redistribution and inflammatory remodeling

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by progressive metabolic dysfunction accompanied by persistent hepatic inflammation. Increasing evidence implicates Caveolin-1 (Cav-1) in metabolic diseases; however, whether Cav-1 coordinately regulates hepatic lipid metabolism and inflammatory remodeling during MASLD progression remains unclear. Here, we investigated the pathogenic role and mechanisms of Cav-1 in MASLD using clinical samples and complementary in vivo and in vitro models. Methods Serum Cav-1 was measured in healthy controls and patients with MASLD-related cirrhosis. Dynamic Cav-1 secretion was validated in LPS-challenged RAW264.7 macrophages and MCD-induced MASLD mice. Cav-1 knockout mice and Cav-1-silenced AML-12 hepatocytes were used to investigate Cav-1 functions in hepatic lipid metabolism and inflammatory injury. Hepatic steatosis was evaluated by Oil Red O and Nile Red staining. Systemic and intrahepatic lipid profiles, ABCA1 expression, and the AMPK/ACC lipogenic axis were analyzed to define lipid metabolic reprogramming. Hepatic pathology, myeloid cell infiltration and proinflammatory cytokines were assessed by H&E staining, NAS scoring, Sirius Red staining, flow cytometry and qRT-PCR. Serum transaminases were measured to quantify hepatocellular damage. Results Circulating Cav-1 was significantly increased in patients with MASLD-associated cirrhosis, MCD-fed mice, and LPS-stimulated macrophages, suggesting Cav-1 is induced in response to early metabolic stress. Genetic ablation or silencing of Cav-1 substantially ameliorated hepatic steatosis, hepatocellular injury, and inflammatory responses both in vivo and in vitro . Consistently, Cav-1 deletion alleviated hepatic fibrosis in mice. Mechanistically, Cav-1 deficiency enhanced the inhibitory phosphorylation of acetyl-CoA carboxylase (ACC), suppressing ACC catalytic activity independent of total ACC protein levels and restraining hepatic de novo lipogenesis. In parallel, loss of Cav-1 upregulated hepatic ABCA1 expression to promote cholesterol efflux and facilitate adaptive lipid redistribution between the liver and peripheral circulation. Furthermore, Cav-1 deletion robustly reduced recruitment of proinflammatory monocytes/macrophages and neutrophils, reshaping the proinflammatory hepatic microenvironment. Conclusions Our findings identify Cav-1 as an upstream coordinator of hepatic immunometabolic remodeling during MASLD progression. By concurrently modulating ACC-dependent de novo lipogenesis, ABCA1-mediated cholesterol trafficking, and innate immune cell recruitment, Cav-1 integrates metabolic and inflammatory responses that drive hepatic steatohepatitis and subsequent fibrosis progression. Targeting Cav-1 may therefore represent a promising therapeutic strategy for MASLD.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.1971138
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Caveolin-1 deficiency alleviates MCD-induced hepatic steatosis by coordinating ACC inhibitory phosphorylation, cholesterol redistribution and inflammatory remodeling

Baian Chen, 严玉霖, Ruirui Li, Yixue Shu et al.
3 links
Frontiers in Immunology
Liver Disease Diagnosis and Treatment
article

Caveolin-1 deficiency alleviates MCD-induced hepatic steatosis by coordinating ACC inhibitory phosphorylation, cholesterol redistribution and inflammatory remodeling

Baian Chen, 严玉霖, Ruirui Li, Yixue Shu, Guoqin Gao, Quan Sun
article en

Abstract

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by progressive metabolic dysfunction accompanied by persistent hepatic inflammation. Increasing evidence implicates Caveolin-1 (Cav-1) in metabolic diseases; however, whether Cav-1 coordinately regulates hepatic lipid metabolism and inflammatory remodeling during MASLD progression remains unclear. Here, we investigated the pathogenic role and mechanisms of Cav-1 in MASLD using clinical samples and complementary in vivo and in vitro models. Methods Serum Cav-1 was measured in healthy controls and patients with MASLD-related cirrhosis. Dynamic Cav-1 secretion was validated in LPS-challenged RAW264.7 macrophages and MCD-induced MASLD mice. Cav-1 knockout mice and Cav-1-silenced AML-12 hepatocytes were used to investigate Cav-1 functions in hepatic lipid metabolism and inflammatory injury. Hepatic steatosis was evaluated by Oil Red O and Nile Red staining. Systemic and intrahepatic lipid profiles, ABCA1 expression, and the AMPK/ACC lipogenic axis were analyzed to define lipid metabolic reprogramming. Hepatic pathology, myeloid cell infiltration and proinflammatory cytokines were assessed by H&E staining, NAS scoring, Sirius Red staining, flow cytometry and qRT-PCR. Serum transaminases were measured to quantify hepatocellular damage. Results Circulating Cav-1 was significantly increased in patients with MASLD-associated cirrhosis, MCD-fed mice, and LPS-stimulated macrophages, suggesting Cav-1 is induced in response to early metabolic stress. Genetic ablation or silencing of Cav-1 substantially ameliorated hepatic steatosis, hepatocellular injury, and inflammatory responses both in vivo and in vitro . Consistently, Cav-1 deletion alleviated hepatic fibrosis in mice. Mechanistically, Cav-1 deficiency enhanced the inhibitory phosphorylation of acetyl-CoA carboxylase (ACC), suppressing ACC catalytic activity independent of total ACC protein levels and restraining hepatic de novo lipogenesis. In parallel, loss of Cav-1 upregulated hepatic ABCA1 expression to promote cholesterol efflux and facilitate adaptive lipid redistribution between the liver and peripheral circulation. Furthermore, Cav-1 deletion robustly reduced recruitment of proinflammatory monocytes/macrophages and neutrophils, reshaping the proinflammatory hepatic microenvironment. Conclusions Our findings identify Cav-1 as an upstream coordinator of hepatic immunometabolic remodeling during MASLD progression. By concurrently modulating ACC-dependent de novo lipogenesis, ABCA1-mediated cholesterol trafficking, and innate immune cell recruitment, Cav-1 integrates metabolic and inflammatory responses that drive hepatic steatohepatitis and subsequent fibrosis progression. Targeting Cav-1 may therefore represent a promising therapeutic strategy for MASLD.

Frontiers in ImmunologyVol. 17
Capital Medical University (CN)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon